NCT02556307

A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 270 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this Slovenian, multi-center, observational study, the effectiveness of standard of care Peginterferon alfa-2a + ribavirin treatment in adult patients with chronic hepatitis C (CHC) is examined. Patients were treated for 24- or 48-weeks, as prescribed by the treating physician, followed by a 24-week follow-up period.

Conditions

• Hepatitis C, Chronic

Interventions

Type	Name	Description
DRUG	Peginterferon alfa-2a	Peginterferon alfa-2a according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
DRUG	Ribavirin	Ribavirin according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.

Timeline

• Start date: 2009-03-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2015-09-22
• Last updated: 2016-02-15
• Results posted: 2016-02-15

Locations

4 sites across 1 country: Slovenia